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Genetically modiﬁed (GM) crops may contain newly expressed proteins that are described as ‘‘intracta-
ble’’. Safety assessment of these proteins may require some adaptations to the current assessment pro-
cedures. Intractable proteins are deﬁned here as those proteins with properties that make it extremely
difﬁcult or impossible with current methods to express in heterologous systems; isolate, purify, or con-
centrate; quantify (due to low levels); demonstrate biological activity; or prove equivalency with plant
proteins. Five classes of intractable proteins are discussed here: (1) membrane proteins, (2) signaling pro-
teins, (3) transcription factors, (4) N-glycosylated proteins, and (5) resistance proteins (R-proteins, plant
pathogen recognition proteins that activate innate immune responses). While the basic tiered weight-of-
evidence approach for assessing the safety of GM crops proposed by the International Life Sciences Insti-
tute (ILSI) in 2008 is applicable to intractable proteins, new or modiﬁed methods may be required. For
example, the ﬁrst two steps in Tier I (hazard identiﬁcation) analysis, gathering of applicable history of
safe use (HOSU) information and bioinformatics analysis, do not require protein isolation. The extremely
low level of expression of most intractable proteins should be taken into account while assessing safety of
the intractable protein in GM crops. If Tier II (hazard characterization) analyses requiring animal feeding
are judged to be necessary, alternatives to feeding high doses of pure protein may be needed. These alter-
natives are discussed here.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ochrome
effector-
glucosyl
Sciences
peration
se; PHA,
ase; RLP,
omains;
D.F. Bushey et al. / Regulatory Toxicology and Pharmacology 69 (2014) 154–170 1551. Introduction
The safety of proteins expressed in genetically modiﬁed (GM)
crops (hereafter ‘‘transgenic proteins’’) has been assessed ever
since scientists ﬁrst had the ability to introduce genes into crops.
There are many opinions on what tests or studies should be
required to scientiﬁcally document that transgenic proteins are
safe, especially when the protein has a history of safe use (HOSU)
or when the expression level is very low.
For the transgenic proteins that are expressed in GM crops
today, a comparative safety assessment process was implemented
in the 1990s in which scientiﬁc studies were carried out to identify
the similarities and differences between a newly developed GM
crop and its conventional (non-GM) counterpart that had a HOSU.
This approach assesses (1) the agronomic/morphological charac-
teristics of the GM crop; (2) macro- and micronutrient composition
and content of important anti-nutrients and toxicants; (3) molecu-
lar characteristics, protein expression, and safety of the newly
introduced protein(s) and their metabolites; and, if appropriate,
(4) the nutritional characteristics of the novel product compared
with that of its conventional counterpart, by testing wholesome-
ness in animal models (e.g., poultry feeding studies). Any identiﬁed
biological differences are assessed further to determine whether
safety issues or concerns exist and then to evaluate the associated
risk. This comparative safety assessment process is also known as
substantial equivalence. This approach has become standard for
safety evaluation of GM crops and has been described in multiple
publications (e.g., Delaney et al., 2008; Hammond, 2008). A more
recent work examined whether the same approach was sufﬁcient
to demonstrate the safety of GM crops that have improved function
by altering endogenous gene expression via RNAi technology or
expression of transcription factors (Parrott et al., 2010). However,
most of the transgenic proteins currently in GM crops are foreign
to the target plant and either toxic to insects or afford tolerance
to commercial herbicides. More importantly, they are amenable
to production of signiﬁcant amounts in heterologous systems, iso-
lation, and subsequent testing. Some proteins from the next gener-
ation of transgenic crops are already proving to be much more
difﬁcult to study. In some cases the transgenic protein will be an
integral part of the substructure of the plant cell, in others it
may be closely related to a protein of the target plant, and in still
others it may be present in the target plant, but be expressed
ectopically in the GM crop. Some proteins may only exist at very
low levels for a short time and be hard to detect and/or identify
in the plant.
There are important questions associated with these ‘‘intracta-
ble’’ proteins. Do these proteins pose a safety issue? Do they need
to be regulated? If necessary, how does one perform a safety
assessment on intractable proteins? While it is unlikely that a pro-
tein that is unstable outside of its normal plant environment can be
toxic to an animal or human, there will be intractable proteins for
which a safety assessment is appropriate, or requested by regula-
tors. In these cases, there are studies that can contribute to the
safety assessment of intractable proteins should it be necessary,
and those studies are the focus of this paper.Table 1
Overview of issues associated with different intractable protein classes.
Prot
Issue Mem
prot
Absence of suitable heterologous expression system U
Low level of expression in GM crop U
Inability to test the functionality of isolated protein U
Inability to determine equivalence of heterologously produced protein and
plant-expressed protein
UIntractable proteins are deﬁned here as those proteins with
properties that make it impossible or extremely difﬁcult to (1)
express in a heterologous system; (2) quantify (due to low levels);
(3) isolate, concentrate, or purify from either heterologous expres-
sion systems or the GM plant; (4) demonstrate functionality of the
isolated protein; or (5) prove equivalency of the heterologously
produced protein with the plant-expressed protein. These limita-
tions are important, because in 2008, a document jointly published
by the International Life Sciences Institute (ILSI) and the Interna-
tional Food Biotechnology Committee (IFBiC) recommended a sys-
tematic weight-of-evidence tiered approach to assess the safety
of novel proteins expressed in GM crops (Delaney et al., 2008).
Safety evaluation of the candidate novel protein begins with a Tier
I potential hazard identiﬁcation, which includes HOSU, bioinfor-
matics analysis, mode of action, in vitro digestibility and stability
in the presence of simulated gastric ﬂuid (SGF) and simulated intes-
tinal ﬂuid (SIF), expression level, and dietary intake evaluation. If
these elements of the safety evaluation are satisfactory, then it
can be concluded that the protein is safe to express in GM crops.
If, however, the safety of the protein cannot be conﬁrmed in the Tier
I analyses, then Tier II hazard characterization studies should be
considered. These Tier II studies could include acute and possibly
repeated-dose toxicity studies in mice or rats and, if warranted,
hypothesis-based evaluations. Some of the Tier I tests and all of
the Tier II hazard tests require grams of protein. However, produc-
tion, isolation, or concentration of sufﬁcient quantities of function-
ally active proteins for use in safety studies may not be possible. For
example, integral membrane proteins are not only difﬁcult to
express in heterologous systems, they (due to their hydrophobicity)
have very limited solubility in the types and levels of vehicles that
would be appropriate for toxicity testing. Many proteins form sus-
pensions at high concentrations, but membrane proteins oligomer-
ize into uncharacterizable forms. The question then becomes, how
does one provide appropriate scientiﬁc data to support the safety
assessment of a GM crop that contains an intractable protein?
Classes of proteins in which all or at least some of the proteins
might be intractable include (1) membrane proteins, (2) signaling
proteins, (3) transcription factors, (4) N-glycosylated proteins,
and (5) resistance (R)-proteins. The characteristics that could ren-
der each type of protein intractable are discussed along with tools
and science-based solutions for safety assessment of intractable
proteins. The scope of this paper focuses only on the safety assess-
ment and functionality of the intractable protein itself and not the
safety of the crop containing the protein.
2. Classes of intractable proteins
Table 1 summarizes the classes of intractable proteins discussed
in this section.
2.1. Membrane proteins
2.1.1. Deﬁnition of membrane proteins
‘‘Membrane protein’’ is a biochemical term used to describe
polypeptides that associate with lipid membranes, either stablyein class
brane
eins
Signaling
proteins
Transcription
factors
N-glycosylated
proteins
R-
proteins
U U
U U U
U
U U U U
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functions ranging from metabolite exchange to cell signaling, and
their interaction with the membrane is critical to their biological
activity and function. They can act as enzymes, electron carriers,
ion channels, transporters, pumps, photosynthetic reaction cen-
ters, or receptors. Because of their involvement in many critical
cellular functions, select membrane proteins are of major interest
for introduction into GM crops.
Classiﬁcation of membrane proteins is based on the physical
properties of the protein, which can be ascertained either by struc-
tural prediction using bioinformatics (e.g., hydrophobicity plots) or
by experimental approaches.
The mechanisms used by proteins to associate with membranes
are diverse and therefore necessitate sub-classiﬁcation. Based on
their location or interaction with the biomembrane, membrane
proteins can be integral, peripheral, or lipid-anchored (Fig. 1).
Examples of proteins in each class are provided in Table 2.2.1.2. Integral membrane proteins
An integral membrane protein is a protein that spans (or is
embedded into) a lipid bilayer, such as the plasma, nuclear, or
organellar envelope membrane. Integral membrane proteins con-
stitute a considerable proportion of all membrane proteins. They
are involved in various cellular tasks such as catalysis, membrane
transport, and cell signaling. Integral membrane proteins are
intrinsically aqueous-insoluble and recalcitrant to solubilization
with alkaline carbonate or high-salt conditions due to direct
hydrophobic associations with the aliphatic portion of a lipid
membrane. Solubilization of integral membrane proteins requireslipid-anchored protein 
integral protein 
periphera
Fig. 1. Schematic ﬁgure showing the diff
Table 2
Categories and examples of membrane proteins.
Category Example
Integral membrane proteins
Enzymes Fatty acid
Transporters Glucose t
Adhesion proteins Integrins
Receptor proteins Nicotinic
Ion channels Calcium
Multi-enzyme complexes Cytochro
P450 oxi
Peripheral membrane proteins
Enzymes Phosphol
Structural domains that mediate attachment of other proteins Annexins
Transporters Polyisopr
Electron carriers Cytochro
Polypeptide hormones Insulin, a
Lipid-anchored proteins
Glycosylphosphatidylinositol (GPI)-anchored proteins
Prenylated proteins G-protein
Acylated proteins Src famildisruption of the membrane, typically through the use of deter-
gents, to create an artiﬁcial micellar environment for the protein
(Henningsen et al., 2002; Macher and Yen, 2007). The types of sur-
factant(s) (non-ionic, zwitterionic, or ionic) required for complete
solubilization reﬂect the degree of membrane association (Lin
and Guidotti, 2009). Ionic detergents such as sodium dodecyl sul-
fate (SDS) are the most disruptive detergents, many of which have
denaturing properties at high concentrations and temperatures.
2.1.3. Peripheral membrane proteins
Peripheral membrane proteins are associated with cellular
membranes via direct or indirect association with either integral
membrane protein(s) or lipids (Marsh et al., 2002). While some
peripheral membrane proteins may transiently interact with mem-
branes, many interactions are considered stable, and these stable
interactions can be hydrophobic, ionic, or covalent. This association
occurs in vivo, and, when the interaction is stable, under standard
protein extraction conditions in vitro. These proteins can be
stripped from membranes by washing with alkaline carbonate or
high-ionic-strength solutions/buffers. Cell signaling and other
events can be controlled by reversible attachment of proteins to
membranes. Membrane binding may also bring together an
enzyme and its substrates or cause conformational changes in a
protein that lead to its activation.
2.1.4. Lipid-anchored proteins
Perhaps the most difﬁcult membrane proteins to classify solely
from the amino acid sequence are the lipid-anchored proteins. These
are generally soluble proteins that are modiﬁed post-translationallytransmembrane protein 
(integral protein) 
peripheral protein l protein 
erent classes of membrane proteins.
s
desaturase
ransporter
acetylcholine receptor
channel
me P450 (CYP) enzymes in cooperation with NADPH-cytochrome
doreductase (reductase)
ipases, cholesterol oxidases, glycosyltransferase, palmitoyl protein thioesterases
enoid-binding protein
me C, cupredoxins, nitrite reductase, some ﬂavoproteins
ntimicrobial peptides
s, nuclear lamins
y of tyrosine kinases
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membranes in a semi-reversible manner. The types of post-
translational modiﬁcations that are capable of making a protein
amphipathic include, but are not limited to, acylation (e.g.,
myristoylation, palmitoylation; Charollais and Van Der Goot,
2009), prenylation and farnesylation (Resh, 1996), and glucosyl
phosphatidyl inositide (GPI) anchoring (Paulick and Bertozzi,
2008).2.1.5. Intractability issues associated with membrane proteins
Membrane proteins are considered intractable because of the
difﬁculty in developing a suitable heterologous environment for
expression of the recombinant protein, puriﬁcation of the protein
from the membrane fraction, and/or retention of biological activity
once a puriﬁed (or enriched) state is achieved. Most membrane
proteins tend to be a minor component of the cell mass, making
isolation from plant cells difﬁcult and further complicating the
production of large quantities of these proteins in heterologous
systems. Some integral membrane proteins are part of protein
complexes, which pose additional challenges for heterologous
and functional expression (Roos et al., 2012), as it is necessary to
simulate the micro-environment of this highly organized system.
Estimating the activity of the membrane protein when part of a
multi-enzyme complex and comparing this activity when the
membrane protein is expressed in different hosts is a major
challenge.2.1.5.1. Heterologous over-expression of membrane proteins. Due to
the speciﬁc nature of membrane proteins, their heterologous
expression often results in a very limited, or undetectable amount,
of functional protein. If the protein is present at all, it may be pro-
duced as an insoluble form in inclusion bodies, and would there-
fore be nonfunctional. The main factor limiting the over-
expression of membrane proteins is the availability of membrane
space within the expression host, resulting in lower concentration
compared to soluble proteins expressed in the cytoplasm. Even
though the presence of membrane proteins is often tested in Esch-
erichia coli, eukaryotic hosts such as yeast, mammalian, and insect
cells are more likely to be useful for obtaining higher levels of func-
tional membrane protein (see Section 2.4.3). In particular, eukary-
otic expression hosts such as yeast (Pichia pastoris) and insect
(Spodoptera frugiperda) are very useful for membrane protein eval-
uation (André et al., 2006; Asada et al., 2011; Bernaudat et al.,
2011). Photosynthetic bacteria such as Rhodobacter sphaeroides
also provide a similar advantage, as it is possible to create more
membrane space for heterologous membrane proteins by system-
atically disrupting components of the photosynthetic complex,
which is membrane bound. This strategy has been successfully
used to express numerous proteins (Jaschke et al., 2011; Laible
et al., 2004; Roy et al., 2008). Similarly, cell-free protein production
systems can be exploited by supplementing the reaction with
liposomes.
Unlike soluble proteins, membrane proteins have to be properly
inserted into lipid bilayers for them to take on a proper conforma-
tion. The presence of multiple membrane-spanning domains fur-
ther complicates heterologous expression. Although a protein
with only a single membrane-anchoring domain can be expressed
in a soluble form by deleting the domain, it would no longer be
functionally equivalent to the introduced protein in a GM crop.
Furthermore, the assembly of membrane proteins and protein
complexes requires speciﬁc supporting operations, such as mem-
brane insertion and protein folding facilitated by translocon com-
plexes (Bowie, 2005; Skach, 2009). Differences in or absence of
the supporting elements in the heterologous host complicate
expression.2.1.5.2. Puriﬁcation of heterologously expressed membrane pro-
teins. The techniques used to purify soluble proteins, such as
immunoafﬁnity, metal afﬁnity, ion exchange, hydrophobic interac-
tion, and gel-ﬁltration chromatography, have also been used to iso-
late membrane proteins. However, the proteins ﬁrst must be
released from the lipid environment with buffer solutions contain-
ing detergents. The choice of detergent plays an important role in
extracting and purifying membrane proteins in an active form that
is amenable to further downstream applications. A multitude of
biochemical-grade detergents with various combinations of hydro-
phobic and hydrophilic groups are now commercially available for
membrane protein isolation. They have been broadly classiﬁed on
the basis of their polar ‘‘head’’ group as ionic, nonionic, or zwitter-
ionic. Detergents have complex physicochemical properties which
must be taken into consideration to be effectively employed when
working with membrane proteins (Privé, 2007). These properties
include the critical micelle concentration (CMC, the minimal con-
centration required for micelle formation), aggregation number,
micelle molecular mass, hydrophilic–lipophilic balance (HLB),
cloud point, and spectral properties. High-throughput multiwell-
plate-based methods are available for rapid assessment of deter-
gents for extraction and subsequent puriﬁcation of membrane pro-
teins; the identiﬁed detergents are then used for large-scale
puriﬁcation and crystallization (Gabrielsen et al., 2011; Gordon
et al., 2008). When starting expression levels are very low, it is
challenging to obtain membrane proteins of sufﬁcient quantity
for biochemical characterization and X-ray crystallographic struc-
ture elucidation. Tags and fusion partners such as His tag, FLAG
tag, and green ﬂuorescent protein (GFP) are useful not only for
monitoring the expression and localization of membrane proteins
but also for rapid puriﬁcation of membrane proteins using afﬁnity
chromatographic methods (Fan et al., 2011; Rodríguez-Banqueri
et al., 2012), as long as the tag does not affect the functional activ-
ity of the protein. Furthermore, it can be difﬁcult to remove the
fusion tag following puriﬁcation of the protein. However, if the het-
erologously expressed protein is functionally/biochemically com-
parable to the plant-produced protein, irrespective of the
presence of the tag, tagging may provide a method for the produc-
tion/puriﬁcation of the intractable protein.
One additional consideration for the isolation of heterologously
produced membrane proteins concerns protein safety testing (e.g.,
acute oral toxicity testing in mice). It may be very difﬁcult to iden-
tify detergents which can maintain the solubility of the isolated
membrane protein, yet not confound the results of toxicity testing
due to the potential inherent toxicity of the detergent. Further-
more, published data on the acute toxicity of detergents is lacking
(Gad et al. 2006).
2.1.5.3. Activity assessment of membrane proteins. Most membrane
proteins are not functional when removed from a lipid environ-
ment. Reconstitution of puriﬁed membrane proteins into lipo-
somes is essential to reconstitute activity and enable biochemical
studies, and a number of strategies have been used. Four different
types of model membrane systems are reviewed by Shen et al.
(2013). Reconstitution is particularly challenging when more than
one protein is needed to obtain a functional complex, as it requires
simultaneous expression of more than one membrane protein in
addition to reconstituting the protein complex. Because of the
challenges associated with liposome-based membrane protein
reconstitution, nanodiscs are gaining more traction for the assem-
bly of membrane proteins into phospholipid bilayers. The advan-
tage of nanodiscs is that they create a native-like phospholipid
bilayer that keeps membrane proteins in a soluble and functional
form suitable for a number of downstream applications (reviewed
by Bayburt and Sligar, 2010). Even then, co-factors may be needed,
which requires the establishment of the entire system/pathway
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activity by incubating the membrane fractions containing proteins
of interest with labeled substrate and following the formation of
enzymatic products. This method is especially suitable for mem-
brane proteins involved in desaturation of fatty acids. A speciﬁc
example was described by Madduri et al. (2012), who isolated
microsome fractions from recombinant organisms expressing
desaturases, and determined protein activity by incubating with
non-natural substrates.
2.1.5.4. Detection and quantiﬁcation of membrane proteins. Much of
the protein, especially in the case of integral membrane proteins,
can be buried within the membrane, limiting the exposed epitopes
useful for immunological approaches. Even with alternative strat-
egies (e.g., genetic immunization and antibody generation with
synthetic peptides), it may be difﬁcult or impossible with current
methods to produce immunospeciﬁc antibodies because of the
limited surface availability and poor antigenicity of the hydropho-
bic portions.
Selected- or multiple-reaction monitoring by tandem mass
spectrometry, in a ‘‘bottom up’’ manner, was developed for abso-
lute quantiﬁcation (Houston et al., 2011; Stevenson et al., 2012)
of proteins without using antibodies. Mass spectrometry–based
alternative methods may offer an opportunity to detect or quantify
some of the membrane proteins that have been intractable so far.
2.1.6. Example of an intractable membrane protein of agricultural
importance
Diacylglycerol acyltransferase (DGAT) is a membrane protein
associated with in planta high-oil traits. DGAT is the last enzyme
in the triacylglycerol (TAG) synthesis pathway, and it functions to
transfer an acyl group to the sn-3 position of 1,2-diacylglycerol to
produce TAG (Ohlrogge and Browse, 1995). Over-expression of
DGAT has been shown to increase seed oil content in maize and
canola (reviewed by Shen et al., 2010; Oakes et al., 2011). Oil from
DGAT-expressing high-oil crops plants has industrial (biodiesel)
and nutritional applications (high oleic acid) (Zheng et al., 2008).
DGATs are hydrophobic proteins found mainly in the endoplasmic
reticulum (ER) and can contain up to ten putative transmembrane
domains (Lung and Weselake, 2006; Shockey et al., 2006;
Turchetto-Zolet et al., 2011; Yen et al., 2008). Zheng et al. (2008)
predicted that the DGAT1-2 protein had eight transmembrane
domains, while newer models predict nine transmembrane
domains in the DGAT1-2 protein (Fig. 2 [Zhenglin Hou, DuPont Pio-
neer, personal communication]). DGATs are difﬁcult to purify toFig. 2. Predicted struchomogeneity, and the use of detergents and chaotropic agents rou-
tinely used to maintain solubility often results in diminished or
elimination of enzymatic activity (Lung andWeselake, 2006). Char-
acterization studies with recombinant DGAT pose similar solubili-
zation/puriﬁcation challenges (Cao et al., 2011), thus creating
additional challenges for hazard assessment tests.
The level of DGAT1-2 expression in Sf9 insect cells is 1–2 mg/L
(DuPont Pioneer, unpublished results), which makes performing
any toxicology testing of isolated protein very difﬁcult or impossi-
ble using current methods.
There are no published examples of acute or repeated-dose tox-
icity studies for any integral membrane protein. Conventional het-
erologous over-expression systems (E. coli, insect cell, or yeast)
have been used to produce recombinant DGAT (Cao et al., 2011;
Lardizabal et al., 2001; Zheng et al., 2008); however, current capa-
bilities do not allow for the isolation of active DGAT proteins from
these systems in sufﬁcient quantities for rodent studies (gram-
level quantities).
Therefore, history of safe use concerns for DGAT can be
addressed by analyzing and citing reports that identify DGAT iso-
forms in numerous ﬁeld and vegetable crops, thus establishing
prior dietary exposure in animal and humans (Constable et al.,
2007; Section 3.2.1 of this manuscript).
A recent publication by Schroeder et al. (2013) describes the
utility of various membrane transporters for improving sustainable
food production. It provides examples for aluminum tolerance in
acid soils, improved salt tolerance, pathogen resistance, solutions
for iron and zinc deﬁciencies, and nitrogen uptake. These mem-
brane transporters would most likely all be examples of intractable
proteins.
2.2. Signaling proteins
2.2.1. Signaling and signal transduction proteins
These are a diverse group of proteins sharing the unique func-
tion of signaling in the presence of a metabolite, an environmental
factor, or a cellular condition. This signaling in turn elicits a
response, usually through a cascade of events, that results in multi-
ple (pleiotropic) effects. This group includes protein/peptide hor-
mones, environmental sensing/receptor proteins (modiﬁed in
response to stress signals such as nitric oxide, carbon monoxide,
salt, etc.), R-gene products (covered in more detail in Section 2.5),
protein kinases/phosphatases, GTPases, defensins, and ﬂorigens
(Bahyrycz and Konopin´ska, 2007; Batut et al., 2011; Bykova et al.,
2011; Ghanem et al., 2011; Matsoukas et al., 2012; Mithoe andture of DGAT1-2.
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2003; Spadaro et al., 2010).
2.2.2. Intractability issues associated with signaling proteins
Signaling pathways are often tightly controlled and regulated to
avoid abnormal effects on plant growth and development. The
expression levels of many protein kinases and protein phospha-
tases and other signaling proteins have been demonstrated to be
very low in plant tissues. When transgenically expressing one or
more such proteins in plants as a beneﬁcial trait, the expression
usually needs to be limited to a speciﬁc tissue (e.g., pollen, root,
ﬂower, endosperm, or embryo) and/or a certain developmental
stage (Yang et al., 2012), and the expression level needs to be
ﬁne-tuned to minimize any potential adverse effects at the
whole-plant level. In addition, there may be very few homologues
in protein databases, and assessments made based on the safety of
homologous proteins will be difﬁcult to formulate.
An example illustrating the extremely low abundance of some
proteins in this class is phosphoenolpyruvate carboxylase kinase
(PEPCK). Tremendous efforts (e.g., Murmu and Plaxton, 2007;
Saze et al., 2001; Wang and Chollet, 1993) have been undertaken
to purify PEPCK from plants for biochemical characterization and
molecular cloning. In one case (Saze et al., 2001), 0.1 lg of maize
PEPCK was puriﬁed from 2.6 kg of leaves using a time-consuming
and labor-intensive eight-step puriﬁcation procedure. The puriﬁca-
tion factor was about 1.4 million fold.
2.3. Transcription factors
2.3.1. Deﬁnition of transcription factors
Transcription factors and their accessory proteins (TFAPs) regu-
late expression of a variety of genes in eukaryotic systems. Tran-
scription factors bind to a speciﬁc DNA sequence and regulate
transcription of DNA. A typical plant transcription factor consists
of a DNA-binding region, an oligomerization site, a transcription
regulation domain, and a nuclear localization signal (Liu et al.,
1999). TFAPs generally do not bind DNA but interact with other
proteins in the transcription complex to regulate gene transcrip-
tion. Generally transcription factors and TFAPs regulate a family
of genes and exert their inﬂuence by either up-regulating or
down-regulating gene expression (Liu et al., 1999).
Transcription factors can be classiﬁed into different families
based on their structural features. There are currently 84 gene fam-
ilies in the plant transcription factor database (Pérez-Rodríguez
et al., 2010); examples include zinc ﬁnger transcription factors,
bZIP transcription factors, Myb-related transcription factors,
homeodomain transcription factors, Myc bHLH transcription fac-
tors, AP2 transcription factors, and E2F-DP transcription factors
(De Veylder et al., 2007).
Transcription factors and TFAPs could play an important role in
improving intrinsic yield potential and stability, abiotic stress tol-
erance, disease resistance, and nutrient use efﬁciency in plants
(Century et al., 2008). For example, engineering with ZmNF-YB2
resulted in improved corn yields on water-limited soil (Nelson
et al., 2007).
2.3.2. Intractability issues associated with transcription factors
2.3.2.1. In planta transcription factor expression levels. Transcription
factors, such as the Arabidopsis thaliana B-box protein CONSTANS
(CO), accumulate at levels too low to be detected by western blot
analysis, even when functional activity is present (Suárez-López
et al., 2001). Transcription of CO is known to be controlled by a
number of factors, one of which is the circadian clock, which
causes rhythmic oscillations in CO expression (Suárez-López
et al., 2001). In addition, light regulates CO protein stability and
activity (Imaizumi and Kay, 2006). Even for proteins that can beexpressed in a heterologous system, enough functionally active
protein must be isolated from the plant to test for equivalence,
but it may be impossible with current methods to obtain sufﬁcient
quantities at the appropriate purity level to perform the typical
characterization studies to establish equivalence of the in planta
and heterologously expressed proteins.2.3.2.2. Production of transcription factors in heterologous sys-
tems. Transcription factors produced in E. coli are often insoluble
(Al-Samarrai et al., 2007; Yang et al., 2011; Zaret and Stevens,
1995). Obtaining even small quantities of the protein in a solu-
ble, properly folded form requires refolding of the protein from
inclusion bodies, which can be difﬁcult or impossible with cur-
rent methods (e.g., Al-Samarrai et al., 2007; Zaret and Stevens,
1995).2.4. N-glycosylated proteins
2.4.1. Deﬁnition of N-glycosylated proteins
Intractable proteins include those proteins that are stably mod-
iﬁed after translation, allowing for the ‘‘exponential diversiﬁcation
of the genome’’ (Webster and Thomas, 2012). Of all the possible
post-translational modiﬁcations, N-glycosylation is the most com-
mon stable modiﬁcation to impact the physicochemical properties
of the protein. For some proteins, the type and extent of modiﬁca-
tion is speciﬁc to the plant species, the life stage, or the environ-
ment of the plant, or even to each organelle within the cell (see
Rayon et al. (1998) for a review of N-glycosylation in plants).
N-glycosylation occurs in the secretory pathway and is well
conserved in animals, plants, fungi, and social amoebae
(Kukuruzinska and Lennon, 1998). Glycosylation in every species
starts with a common pentasaccharide core sequence, but the sim-
ilarity of the ﬁnal structures varies. Plants have a different oligo-
saccharide makeup than do animals or fungi, and even within
the plant kingdom, the sugars used and their positions in the
substituted oligosaccharide vary among species. Heterogeneity of
glycosylated proteins is observed at three different levels: the
number of glycan side-chains, the extent of glycan modiﬁcation
of the different side-chains of the same glycoprotein, and the het-
erogeneity of oligosaccharide structures on the same N-glycosyla-
tion site (Lerouge et al., 1998).
While isolation and puriﬁcation may be the overriding issue
with some classes of intractable proteins, the more important issue
for N-glycosylated proteins may be showing equivalence or
comparability of the protein produced in the crop plant to that pro-
duced in a model system traditionally used to produce large
amounts of protein. Even if signiﬁcant amounts of protein can be
produced in a heterologous eukaryotic system, the question arises
whether the oligosaccharide substitution pattern will be
equivalent, giving the protein the same folding properties, stability,
and immunoreactivity as in the protein originating from the GM
crop.
Glycosylation pattern can affect the folding and biological activ-
ity of a protein (Bosch and Schots, 2010). Burén et al. (2011)
showed that CAH1 (chloroplast-localized carbonic anhydrase) is
glycosylated at four sites (in some cases, ﬁve), and that glycosyla-
tion is necessary for correct folding, trafﬁcking, and functionality of
the protein. Conversely, the non-glycosylated protein formed
aggregates and was retained in the ER and associated with ER
chaperones, indicating that glycosylation of CAH1 is what facili-
tates folding and ER export. This result calls into question the
validity of any safety assessment performed with naked CAH1 pro-
tein or any substituted glycoprotein. This also demonstrates a case
where HOSU of a protein in one crop may not be applicable to a
safety assessment in a different crop.
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modiﬁed proteins
Given the effects that N-glycosylation can have on protein sta-
bility, immunogenicity, and/or activity of a protein, determining
equivalence may be important, but the inability to determine the
exact nature and composition of N-glycosylated proteins may be
less important for any safety assessment as it should be noted that,
to date, the only glycosylation known to result in adverse effects is
the galactose-a-1,3-galactose that is present on some mammalian
proteins and identical to tick protein glycans. It has been reported
that some individuals bitten by ticks become sensitized to galact-
ose-a-1,3-galactose and respond with allergic reactions following
consumption of large amounts of meat or in other cases following
exposure to the chemotherapeutic drug cetuximab (Berg et al.,
2014; Commins and Platts-Mills, 2013). Though this does not indi-
cate that every N-glycosylated protein should be tested for this
particular moiety, it demonstrates that characterization of N-
linked glycosylation is not likely to be helpful in the safety assess-
ment process.
Glycosylation patterns vary from one organ to another in the
plant and are also dependent on the developmental stage, leading
to a population of proteins with different levels of glycan matura-
tion. The importance of this maturation process to biological activ-
ity is an area of active research (Fanata et al., 2013). N-glycosylated
proteins illustrate the difﬁcult or even impossible situation that
exists when trying to isolate and purify certain plant proteins pro-
duced in a heterologous system and then demonstrate their com-
parability/equivalence with the population of proteins produced
by the GM crop. While not all proteins undergo irreversible post-
translational modiﬁcation and even fewer do so at the stoichiom-
etric level that would be required for proper folding or function,
such proteins present a unique challenge for safety assessment.
2.4.3. Challenges of using different heterologous expression systems for
post-translationally modiﬁed proteins
Post-translational modiﬁcations in proteins limit the types of
expression systems that can be used, particularly in the case of gly-
cosylated proteins, since the glycosylation pattern can be unique to
each organism. While E. coli lacks many of the post-translational
modiﬁcations found in eukaryotes (Brondyk, 2009; Demain and
Vaishnav, 2009), a recent publication (Valderrama-Rincon et al.,
2012) shows that E. coli can be engineered to accomplish N-glyco-
sylation and may offer opportunities in the future. Likewise, P. pas-
toris strains and baculovirus/insect cells have been engineered to
introduce the human glycosylation machinery and to down-regu-
late their endogenous pathways (Hamilton et al., 2006; Harrison
and Jarvis, 2006). However, their application for safety assessment
of GM crops would require the introduction of the glycosylation
pathway of each plant species to be considered, as the pattern or
positioning of glycosylation in the expression system may not be
the same as in the target crop. An example of this is alpha-amylase
inhibitor-1 (aAI) presented later in this section. Even organ speci-
ﬁcity may vary, ranging from the absence of organ speciﬁcity in the
N-glycan processing of phytohemagglutinin (PHA) (Rayon et al.,
1998) to considerable differences in relative abundance of N-gly-
cans between different organs in Brassica napus (Gomord et al.,
2010). Differences in the structure of the glycosyl part of a glyco-
protein can also be seen at different developmental stages
(Brooks, 2004). As a result, the determination of comparability
between N-glycosylated proteins prepared in two different plants,
let alone two different eukaryotes, may be difﬁcult or impossible
with current methods.
2.4.3.1. Example of an N-glycosylated protein. Alpha-amylase inhib-
itor-1 (aAI) from the common bean (Phaseolus vulgaris) demon-
strates the issues of equivalence and multiple products seen withan N-glycosylated protein. Common bean aAI1 is synthesized as
an inactive single-chain precursor that is proteolytically processed
into a and b subunits, which then assemble into a mature aAI-1
molecule displaying inhibitory activity against insect a-amylases
(Franco et al., 2002; Kluh et al., 2005). The two chains, a and b,
form a heteromer and are glycosylated. The dominant form of
the a-chain has both of its glycosylated sites occupied, while the
b-chain’s dominant form has only one of its two potential glycosyl-
ation sites occupied (Sawada et al., 2002; Yamaguchi et al., 1992;
Young et al., 1999).
When the gene from common bean was expressed in pea (Pisum
sativum) seed, the N-glycosylation pattern of the a-amylase inhib-
itor was different from that found in the bean seed (Marsh et al.,
2011; Prescott et al., 2005). While Prescott suggested that the
modiﬁed aAI protein in pea and not the native form was predis-
posed to cause antigen-speciﬁc inﬂammation, Lee et al. (2013)
later showed that this allergenic response was not related to the
aAI protein. Mass spectrometry identiﬁed a complex mixture of
glycosylated aAI proteins. The a chains of aAI from common bean
and GM pea showed the same glycosylation pattern, albeit in dif-
fering proportions, whereas the variation in the b chains was more
complex, but still comparable. However, the difference in glycan
pattern was smaller between the common bean and GM pea than
between the common bean and two other bean species tested.
Additionally, two studies (Campbell et al., 2011; Marsh et al.,
2011) looked at the processing of aAI from the precursors to the
mature a and b chains. Campbell et al. (2011) showed that the
bean had more unprocessed or incompletely processed aAI precur-
sors than the GM pea.
It is worth noting that based on the information described
above, Marsh et al. (2011) concluded that ‘‘the transgenically
expressed and native bean inhibitors can be considered to be ‘sub-
stantially equivalent’ within the wider context of variation within
bean species that are consumed by humans’’.
2.5. Resistance (R)-proteins
2.5.1. Deﬁnition of R-proteins
Resistance (R) proteins in plants are involved in pathogen rec-
ognition and subsequent activation of innate immune responses
(van Ooijen et al., 2008). There are two layers of defense in the
plant immune system. The primary response is referred to as path-
ogen-associated molecular pattern (PAMP)-triggered immunity
(PTI). In PTI, the plant detects a common molecular pattern of a
pathogen such as cell wall fragments, chitin, or peptide motifs in
bacterial ﬂagella as the pathogen tries to invade the plant. Recog-
nition of the PAMP by the host plant receptor triggers the induction
of the primary or basal defense responses (Tameling and Takken,
2008). To inhibit PTI, pathogens have evolved the ability to secrete
effector proteins that suppress the basal plant defense response. In
turn, plants have evolved means to recognize pathogen effectors
and to mount a robust ampliﬁed defense response (effector-trig-
gered immunity [ETI]). In the ETI response, the plant R-proteins
detect the presence of pathogenic effector proteins (also referred
to as avirulence factors) and trigger the defense response. The lat-
ter response is generally faster and stronger and is often accompa-
nied by localized cell death at the infection site (hypersensitive
response) (Jones and Dangl, 2006).
2.5.2. Subclasses of R-proteins
R-proteins display modular domain structures (Fig. 3). Based on
these structural domains, the majority of R-proteins can be divided
into four classes: two intracellular and two extracellular (vanOoijen
et al., 2007). R-proteins in the two intracellular classes contain a cen-
tral nucleotide-binding site (NBS) and a C-terminal leucine-rich
repeat (LRR) domain (NBS-LRR proteins), but the two classes differ
LRR
TIR-NBS-LRR protein 
CC-NBS-LRR protein 
Receptor-like protein (RLP) 
Receptor-like kinase (RLK) 
Fig. 3. Schematic representation of domains found in plant leucine-rich repeat (LRR) R-proteins. Domains are not drawn to scale. TIR, Toll/interleukin-1 receptor; CC, coiled-
coil domain; NB or NBS, nucleotide-binding domain or site; LRR, leucine-rich repeat; TM, transmembrane; Kin, kinase. The linker region (dark blue) is not present in all
proteins, e.g., Rpi-blb1. Figure adapted from Tameling and Takken (2008).
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receptor-like (TIR) domain at the N-terminus (TIR-NBS-LRR pro-
teins) and the other carries a coiled-coil (CC) sequence (CC-NBS-
LRR proteins). R-proteins in the two extracellular classes contain a
predicted extracellular LRR (eLRR) domain at their N termini. This
eLRR is connected via a transmembrane domain to a variable cyto-
plasmic C-terminal region. When the cytoplasmic domain contains
a protein kinase domain, the R-protein is placed in the receptor-like
kinase (RLK) class. If no such domain is present, it is placed in the
receptor-like protein (RLP) class (van Ooijen et al., 2007).2.5.3. Intractability issues associated with R-proteins
Most R-proteins are NBS-LRR proteins. The NBS proteins belong
to the Signal Transduction ATPase with Numerous Domains
(STAND) superfamily of ATPases. NBS-LRR genes have been identi-
ﬁed in all plant species tested and thus seem to be a general mech-
anism of defense against pathogens (McHale et al., 2006).
Despite some key breakthroughs, progress toward understand-
ing how R-proteins function has been slower than anticipated.
Because of their low abundance in the plant cell (and in at least
some cases rapid degradation upon effector recognition [Boyes
et al., 1998]) and the lack of direct interaction between R-proteins
and most of their corresponding effectors (multiprotein complex),
many R-proteins have proven difﬁcult to study biochemically
(Luderer et al., 2001) and are not adaptable to functional assays.2.5.4. Example of an R-protein
The Rpi-blb1 gene from Solanum bulbocastanum encodes the
Rpi-blb1 protein, which is a member of the CC-NBS-LRR class of
R-proteins. Rpi-blb1 protein confers resistance to Phytophthora
infestans, which causes potato late blight disease (van der Vossen
et al., 2003). The Rpi-blb1 gene has been introduced by genetic
engineering into different potato cultivars in recent years
(Vleeshouwers et al., 2008). In resistant plants, Rpi-blb1 protein
detects the presence of effector protein Avrblb1 (IPI-O family class
I) from P. infestans and triggers a host defense response.
Little information is available regarding Rpi-blb1 protein
expression in GM crops. There appears to be low basal expression
of most R-genes (Kramer et al., 2009). Despite major advances in
understanding plant disease resistance mechanisms, it is still
unclear exactly how Rpi-blb1 protein functions in the plant. No
in vitro functional assay has been developed for Rpi-blb1 protein
to date, so it will be difﬁcult to conﬁrm the functionality of the bac-
terially produced Rpi-blb1 protein.
Accordingly, it is not surprising that the R-gene product Rpi-blb1
was not detectable by standard ELISA such as typically used for
measuring protein levels in transgenic plants (BASF Plant Science,unpublished results). This Rpi-blb1 ELISA has a lower limit of detec-
tion of approximately 100 ng/g dry weight of leaf material, corre-
sponding to 100 ppb. Proteins encoded by R-genes are believed to
be present at extremely low levels, and literature reports focus on
transcript levels rather than protein levels (Kramer et al., 2009). If
Rpi-blb1 is assumed to be present at only one copy per cell and
we assume that there are approximately 100,000 cells/g leaf (calcu-
lated from 5000 cells/leaf [Autran et al., 2002] and 50 mg per Ara-
bidopsis leaf), then there would be approximately 18 fg Rpi-blb1/
g leaf (0.018 parts per trillion [ppt]; based on Rpi-blb1 MW of
110,000 and 6.02  1023 molecules/mole). Even if this calculation
is 1000-fold off, detecting 18 ppt is not within the current capabil-
ities of today’s technologies. Thus, Rpi-blb1 is clearly an example of
an intractable protein due to its very low level of expression. The
need to perform a comprehensive safety assessment is questionable
because the exposure is virtually nonexistent. (If exposure is
calculated based on 200 kg of potato consumption/person/year
[e.g., for Belarus in 2009; FAOSTAT, http://faostat.fao.org/site/609/
DesktopDefault.aspx?PageID = 609#ancor] and 18 fg/g, the expo-
sure is only 3.6 ng/year.) Furthermore, attempts to produce higher
quantities of Rpi-blb1 in plant cells using constitutive high-level
promoters were unsuccessful, perhaps due to the role the protein
plays in protecting the plant from the pathogen.3. Safety assessment of intractable proteins
The previous pages have described numerous classiﬁcations of
intractable proteins and some of their possible applications in agri-
cultural biotechnology. As a preface to any discussion about the
safety of intractable proteins, it should be stressed that to date
none of these classes of proteins has ever presented any evidence
of hazard. Therefore, the mere use of a protein that would be con-
sidered intractable in a GM plant does not necessarily indicate that
the expression of that protein presents any risk. Nevertheless, it is
anticipated that regulatory authorities will request safety data for
intractable proteins when used in GM plants. The following sec-
tions of this document will review how the components of protein
safety assessment could be applied to intractable proteins.
If a protein is so unstable that it cannot be isolated, or it requires
a membrane-type environment to be active, any degradation by
digestion or processing would render the protein inactive; there-
fore, there may be little to gain, if anything, from any further safety
testing. Hammond et al. (2013) recommended considering addi-
tional factors in protein safety assessment, including the impact
of food processing on dietary exposure of introduced proteins,
HOSU, and potential for harmful interactions between introduced
proteins in crops containing multiple traits. For toxicology testing,
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study should not be required if the introduced protein is structur-
ally/functionally related to a family of proteins that has a HOSU
based on bioinformatics and literature review, the protein is sus-
ceptible to inactivation during normal processing and cooking of
foods, and the mode of action has been established (Hammond
et al., 2013). These principles, built upon those recommended by
Delaney et al. (2008), highlight that testing of proteins in animal
toxicology studies may not be required for the safety assessment
of GM proteins. These principles should be equally, if not more,
applicable to intractable proteins.
However, if this rationale is not considered sufﬁcient to predict
the safety of an intractable protein, there are a number of tools that
can be used. Many of these tools are adapted from well-established
methods used today with ‘‘normal’’, tractable proteins, but some
methods are new in that they offer a way to examine the proper-
ties of a protein in an indirect or novel way. These tools include
HOSU (Section 3.2.1), bioinformatics (3.2.2), threshold of toxicolog-
ical concern (3.2.3), use of substitutes and enriched fractions
(3.2.7), mode of action and speciﬁcity (3.2.5), ‘‘targeted omics’’
(3.2.6), acute and repeated dosing (3.3.1), and in vitro assays
(3.3.2). While no single property determined from the methods
mentioned above may determine the safety of the protein, some
combination of properties can provide a weight of evidence toward
the safety of the protein being studied.
3.1. Safety evaluations for intractable proteins using the weight-of-
evidence approach
The weight-of-evidence approach is designed to systematically
evaluate and identify potential hazards of novel proteins by com-
paring their physical properties, sources, and sequences with those
of known protein toxins or allergens (Table 3). Tier II testing may
not be needed if the protein of interest has the following character-
istics: (1) has a HOSU, (2) does not show structural similarity to
known protein toxins or allergens, (3) has expression levels that
can be measured to determine exposure, (4) is readily digestible,
and (5) acts as intended (Delaney et al., 2008).
Since intractable proteins may not be able to be measured or
subjected to the tests mentioned earlier, they present a unique
challenge for safety assessment. Protein digestibility/stability,
equivalency, expression level/exposure, and acute and repeated
toxicity are difﬁcult or impossible to measure for the reasons dis-
cussed in section 2. In the remaining part of this paper we discuss
different strategies within the context of the weight-of-evidence
testing approach as applied to intractable proteins.
3.2. Tier I testing
3.2.1. HOSU for intractable proteins
The weight-of-evidence approach currently used to assess the
safety of a novel protein (Codex Alimentarius Commission, 2009)Table 3
Weight-of-evidence elements.
Element Purpose
Tier I: Potential hazard identiﬁcation
History of safe use (HOSU) Documents
Bioinformatics analysis/ homology searches Flags struct
Protein levels in edible parts of the plant and dietary intakes Used to est
In vitro digestibility and heat stability Determines
under phys
Mode of action and functional speciﬁcity Provides ev
Tier II: Hazard characterization
Acute toxicity assessment Assesses po
Repeated-dose toxicity assessment Examines b
Adapted from Delaney et al. (2008).considers a variety of different factors. The safety assessment of
any protein should begin with gathering historical information
about prior human exposure or consumption, which is compiled
into the HOSU. The degree to which HOSU can be established for
a given protein can provide valuable information about whether
further testing may be necessary to identify potential hazards asso-
ciated with the protein (Delaney et al., 2008).
Important factors in establishing a HOSU include the following
(Constable et al., 2007):
 The safety of the donor organism from which the protein was
obtained
 Evidence of dietary or environmental exposure to the protein
 Consumption levels of the protein in different populations
 The results of any animal studies previously conducted with the
protein and/or similar proteins
 Epidemiological studies
Establishing the safety of an introduced protein does not neces-
sarily require that the exact protein has previously been contained
in foods. Rather, safety can be established based on structural or
functional similarity to proteins with a HOSU. Determining the
degree of similarity required between an introduced protein and
an existing protein with a HOSU is usually established through bio-
informatics analyses on a case-by-case basis (Delaney et al., 2008).
Some information about the HOSU should be readily available
regardless of whether a protein is simple to isolate and character-
ize or intractable. This information should include the safety of the
donor organism and, if available, evidence related to dietary expo-
sure to the protein from that source. What is particularly impor-
tant in the case of intractable proteins is that this information
can be obtained without having to isolate any puriﬁed protein.
3.2.2. Bioinformatics approaches for safety assessment of intractable
proteins
At an early stage of the safety evaluation, bioinformatics analy-
ses are conducted to compare the amino acid sequence of a candi-
date novel protein with known protein allergens and toxins
(Delaney et al., 2008; Ladics et al., 2011). To evaluate the potential
allergenicity of a candidate novel protein, the protein sequence is
compared with sequences of known allergenic proteins that are
maintained in a database at the Food Allergy Research and
Resource Program (FARRP), University of Nebraska (http://
www.allergenonline.org/). Potential homologies between the
amino acid sequence of the candidate protein and those of proteins
in the allergen database are evaluated using alignment algorithms
(Pearson, 2000; Pearson and Lipman, 1988). Alignments can be
reviewed for identities greater than or equal to the 35% threshold
over 80 or more amino acids in conjunction with the E scores
(Ladics et al., 2011). Based on Codex Alimentarius (2009), the
amino acid sequence is also evaluated if there are eight contiguous
identical amino acid matches to the sequences of allergenicfamiliarity, already consumed in the existing food chain
urally similar toxic, allergenic, pharmacological, or physiological active proteins
ablish exposure estimates
likelihood that the GM protein will be denatured and/or degraded
iological conditions or during cooking/processing
idence of biological function and speciﬁcity of the protein
tential mammalian acute toxicity
road range of possible adverse outcomes/effects over 28 days
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that evaluation of eight contiguous identical amino acid matches
to the sequences of allergenic proteins is not predictive and may
lead to false positives (Herman et al., 2009; Ladics et al., 2011).
Bioinformatics tools are also used to compare the sequence of
candidate novel proteins with those of other proteins to determine
whether they are similar to known protein toxins. While this type
of analysis can be useful in establishing similarity between candi-
date novel proteins and toxic proteins, there is currently no univer-
sally available database in which the sequences of toxic proteins
are maintained and curated, nor is there a uniform standard
against which similarity can be established. What would be very
useful in practice is multiple sequence alignment coupled with
secondary structure assignment and the predictions that could be
made from it, particularly if they were combined with a threading
program for 3-dimensional modeling. Nevertheless, bioinformatics
is a powerful tool that can be used in identifying sequence similar-
ity between novel proteins and proteins that have a documentable
history of causing adverse effects. In a similar way, bioinformatics
can be equally important in demonstrating similarity to proteins
with a HOSU. As with HOSU, it is important to note that this infor-
mation can be obtained without isolating the protein.
3.2.3. Expression levels in edible plant parts, dietary intake, and
threshold of toxicological concern
Most intractable proteins are expressed at very low concentra-
tions in plants and hence the dietary exposure of the protein to
humans will be very low. Risk is a product of hazard and exposure,
and exposure to these low-expressing intractable proteins will be
minimal (see, e.g., section 2.5.4). Combining that with the likeli-
hood that hazard (toxicity) data will not be available or will be lim-
ited, how can risk be assessed in this scenario?
A risk assessment strategy called the threshold of toxicological
concern (TTC) is actively being discussed for chemicals. Application
of the TTC concept is recommended for ranking and prioritizing
risks from exposure to substances for which toxicity data are lack-
ing or limited, but which may be present in food at low concentra-
tions and for which exposure analysis can provide sound intake
estimates. The TTC for chemicals is 0.15 lg/person/day or higher
(up to 1800 lg/person/day), depending upon whether the chemical
has any structural similarity with known carcinogens and on its
toxic potency (Kroes et al., 2000, 2004). Chemicals are divided into
three groups depending on the relatedness of their chemical struc-
tures to those of other chemicals that pose minimal safety con-
cerns or, on the other hand, suggest the potential for toxicity
(Kroes et al., 2000, 2004). Similarly, the TTC concept should be
applicable in assessing the toxicological risk from dietary exposure
of compounds produced in the edible parts of GM crops.
The main reason that the TTC concept has not been applied to
allergenicity during safety assessment of proteins is that the
thresholds of exposure for most food protein allergens have not
yet been determined. The levels required for sensitization and
induction are unknown for most allergens and a very small amount
(at ppm level) can elicit an allergic reaction (Taylor et al., 2010).
There is ongoing research in this area to determine the minimum
allergen doses capable of inducing primary sensitization or elicita-
tion, but more work has to be done to deﬁne the threshold values
for most allergens (Kruizinga et al., 2008; Taylor et al., 2009).
In the case of intractable proteins, if the level of the protein is
extremely low in the GM crop and the protein is not similar to
known allergens, i.e., does not share signiﬁcant amino acid
sequence homology with a known allergen, the TTC concept could
be applied. In addition to the low level of many intractable pro-
teins, normal food processing can denature and inactivate the pro-
tein, which may further decrease the dietary exposure of active
protein (Hammond and Jez, 2011).Efforts have already been made to determine the TTC for pro-
teins. Hammond and Cockburn (2008) estimated a TTC value for
protein toxicity based on a no-observed-adverse-effect level
(NOAEL) calculated from data available for 40 subchronic studies.
The calculated NOAEL across these 40 subchronic studies was
249 mg/kg, which when divided by a 100-fold uncertainty factor
provided a TTC of 2.49 mg/kg or 149 mg/adult person/day (assum-
ing 60-kg body weight [BW]). Acute TTC based on 30 acute studies
was calculated to be 17.9 mg/kg BW, or 1074 mg/adult person/day.
Comparison of these threshold levels to actual dietary exposure
levels assumes a ‘‘worst-case’’ scenario in which there is no loss
of the introduced protein when the GM crop is processed into food.
It might be possible to further develop the TTC concept based on
additional protein toxicity data available to determine TTC values
for proteins or structural classes of proteins.
Hammond and Cockburn (2008) illustrated how the TTC con-
cept can be applied to proteins introduced into GM crops, using
CP4 EPSPS (5-enol-pyruvylshikimate-3-phosphate synthase)
protein as an example. CP4 EPSPS is present in grain from glyphos-
ate-tolerant maize at a level of approximately 14 ppm (Hammond
and Cockburn, 2008). EPSPS has a HOSU and CP4 EPSPS has no
homology to known toxins or allergens (Harrison et al., 1996;
Padgette et al., 1996). Making the most conservative assumption,
i.e., that 100% of the corn consumed is derived from glyphosate-
tolerant maize, the estimated intake of introduced protein is
0.004 mg/kg BW/day or 0.27 mg/person/day for CP4 EPSPS
(Hammond and Cockburn, 2008). This exposure level is 600-fold
below the calculated TTC for proteins of 2.49 mg/kg described
above. If the effects of normal food processing are taken into
account, the actual dietary exposure of CP4 EPSPS protein
decreases by another 100-fold, which results in60,000-fold lower
exposure than the chronic exposure TTC level (Hammond et al.,
2013).
Hence, TTC could be applied to some of the proteins introduced
into GM crops, especially intractable proteins, many of which are
expressed at very low levels that might be reduced even further
during food processing. If the dietary exposure level of a particular
introduced protein is above the TTC, it does not mean that the pro-
tein is not safe for consumption; rather, it indicates that appropri-
ate toxicity studies may be warranted to further assess the safety
of the novel protein.
If the dietary exposure of the protein is below the TTC, then
there is minimal toxicological concern associated with the protein.
Adoption of the TTC concept in safety assessment of introduced
proteins could help to avoid the use of large numbers of animals
in toxicity studies. If protein dietary exposure of the introduced
intractable protein is less than the TTC, there is a HOSU, and the
bioinformatics search raises no concerns, then there is no scientiﬁc
justiﬁcation for further toxicological testing.
3.2.4. In vitro digestibility and heat stability using enriched protein
preparations
The stability of the protein to gastric digestion is a factor con-
sidered when assessing its allergenicity, activity, or toxicity poten-
tial. A protein that is rapidly digestible by a protease (e.g., pepsin)
is theorized to have less potential to exert adverse health effects
when consumed than one that is less readily digested. An aller-
genic protein is assumed to be stable long enough to cross the
mucosal membrane of the intestinal tract, where absorption
occurs. The existence of signiﬁcantly sized protease-resistant frag-
ments, generally accepted as larger than approximately 3000–
3500 MW (Bannon et al., 2002; Lack et al., 2002), after simulated
gastric digestion suggests that further studies might be appropriate
to assess whether the protein has the potential to be allergenic,
e.g., sequential digestion in gastric ﬂuid followed by intestinal
ﬂuid, comparison with known allergenic epitopes, heat stability,
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toxicity potential. Both allergenicity and toxicity potential are eval-
uated (separately) using a weight-of-evidence approach of which
digestibility and heat stability are just two parameters.
For intractable proteins that cannot be heterologously
expressed and puriﬁed, digestibility could be monitored using an
enriched preparation of protein and quantifying the absolute abun-
dance of that protein using modern mass spectrometry–based
approaches. For example, for a fatty acid–modifying enzyme that
is localized to ER membrane, puriﬁed microsomes from the host
plant that contain the recombinantly expressed protein could be
tested for enrichment by using antibodies or mass spectrometry.
This microsome preparation could then be subjected to an
in vitro digestion assay simulating the human gut, and the abun-
dance of this protein monitored post-digestion.
An excellent example of this approach is the preliminary safety
assessment of the membrane-bound protein delta 9 desaturase
(D9DS), recently reported by Madduri et al. (2012). The weight of
evidence for this intractable protein included both heat and digest-
ibility studies on enriched or microsomal preparations. These data
along with HOSU, bioinformatics, and mode of action were used to
support the human health safety of D9DS as expressed in oilseed
crops.
Furthermore, when the level of an intractable protein is too low
to detect within the transgenic plant, it is unlikely to be allergenic
because allergenic proteins are generally expressed at a high per-
centage of the protein in the food (Lehrer et al. 2002).
3.2.5. Mode of action and speciﬁcity
The mode of action of a transgenic protein can be helpful in
establishing the range of biological activity that is being introduced
into a plant. In the case of intractable proteins, it is likely that tra-
ditional biochemical studies will not be available, but indirect
methods can provide useful tools to establish the mode of action
and functional speciﬁcity of intractable proteins. For example, bio-
informatics can be used to make hypotheses for mode of action on
the basis of primary sequence and structural homology to speciﬁc
functional class of proteins.
Carbonell and Faulon (2010) developed a web-based method to
predict promiscuity of enzymes using vector machine-trained
molecular signature sequences. Su and Lee (2013) used a slightly
different approach and developed a method to predict kinase-spe-
ciﬁc phosphorylation sites on protein three-dimensional structures
using a support vector machine approach in conjunction with
information on linear motifs and spatial amino acid composition.
The approaches outlined above could be used to demonstrate
that the protein has a very narrow spectrum of activity and there-
fore its expression in a plant would be expected to have no activity
other than the intended activity. Uncertainty about the safe use of
any particular protein is reduced if the mode of action of the pro-
tein is demonstrated to be not deleterious to the human or animal
consuming the protein.
3.2.6. Additional approaches to support the safety assessment of
intractable protein traits
Directed or targeted ‘‘omics’’ (e.g., proteomics, metabolomics,
transcriptomics) represent fast-evolving and powerful technolo-
gies which might also provide data useful for establishing the
mode of action of newly introduced traits. These tools have their
most value when employed during the discovery or trait identiﬁ-
cation phase of product development rather than during the
safety assessment phase. The application of these methods will
require in planta expression of the intractable protein, but they
beneﬁt from not requiring puriﬁcation of the actual protein.
Among the currently available ‘‘omics’’ approaches, transcripto-
mics offers the most complete view of the cognate biomoleculeand could therefore be a good choice when little information is
available about the mode of action of a given protein. With the
advent of parallel short-sequencing approaches, an entire tran-
scriptome can be cataloged quickly and inexpensively. While col-
lecting these data is becoming cheaper and easier, organizing the
morass of information is still arduous and it is in the interpreta-
tion of these data where signiﬁcant costs begin to accrue. Fur-
thermore, since transcript and protein expression levels are not
always concordant (Hajduch et al., 2010), comparative proteomics
may also be advisable to interrogate the plant system for safety
(e.g., allergen equivalency) or mode of action. Thus, while trans-
criptomics technology can provide a measure of equivalency in
perhaps the most global manner of any ‘‘omics’’ approach, it is
merely one piece of the puzzle in a systems approach to approx-
imate a plant.
The utility of any ‘‘omics’’ approaches in the context of safety
assessment of GM crops is still emerging as baseline omics dat-
abases continue to be developed. As with any aspect of safety
assessment, experiments need to be properly controlled and
well-deﬁned, as these technologies can lead to unsupported or
worse, erroneous conclusions if improperly used or interpreted.
For example, two plants grown in the same ﬁeld under the same
growing conditions will always show variation in analyte composi-
tion, which in the absence of biological context (i.e., genetic and
environmental variation), makes equivalence assessments difﬁcult
and/or meaningless. Therefore, a targeted approach with a speciﬁc
trait-connected application, such as the impact of an introduced
enzyme on a speciﬁc metabolic pathway, may be more appropriate
and useful.
3.2.7. Protein samples in support of safety assessment
3.2.7.1. Equivalence of plant-produced and substitute protein sam-
ples. Due to low expression of most transgenic proteins within the
GM crop, safety studies are routinely conducted by using highly
puriﬁed protein substitutes derived from heterologous expression
systems. In equivalence studies, key parameters of the protein sub-
stitute are established to conﬁrm biochemical and functional
equivalence to the plant protein, and thus to conﬁrm its suitability
for such studies as digestibility and toxicological studies (Raybould
et al., 2013). While this approach may not be applicable for many
intractable proteins due to extremely low expression levels or the
inability to assess functional activity (e.g., transcription factors
[section 2.3.2] and most signaling proteins [section 2.2.2]), it
should be recognized that bioinformatics and molecular analytical
tools can be used to demonstrate that the protein expressed in the
plant at a low level is in fact equivalent to the substitute prepared
in another system. The combination of experimental and bioinfor-
matics data can provide meaningful evidence to support the equiv-
alence of the two proteins.
When the equivalence of the heterologously expressed protein
cannot be experimentally determined for reasons described above,
the use of heterologously expressed protein substitutes can pro-
vide valuable information in support of the safety assessment of
the intractable protein. This is a case where bioinformatics can pro-
vide substantial evidence supporting the equivalence of the protein
substitute. In silico molecular modeling that predicts similar fold-
ing or surface distribution of residues may also be a powerful tool
to demonstrate the equivalence of the substitute protein. Many
molecular modeling analyses have been shown to give reliable pre-
dictions, particularly when the structure of a closely related homo-
logue is used as a starting point (Jaroszewski, 2009; Schlick et al.,
2011).
3.2.7.2. Enriched protein samples derived from plant material. In the
case where the protein substitute cannot be expressed in a heter-
ologous system, enriched protein samples (i.e., concentrated and
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valuable alternatives when directly applied in safety studies such
as acute toxicity studies. Enriched protein samples containing a
40-fold increase of the transgenic protein have been reported
(ANZFA, 2000), and although concentrations may be much lower
than suggested by the Organisation for Economic Co-operation
and Development (OECD) guidelines, these studies will provide a
certain level of conﬁdence in safety assessments because they
employ the same plant protein to which humans, animals, and
the environment will be exposed.
3.3. Tier II testing
In the event that data gaps are identiﬁed or that information is
not conclusive during Tier I testing, individual studies contained
within Tier II may be considered. Because of the nature of intracta-
ble proteins, it is almost certain that the study design will differ
from those traditionally conducted with novel proteins. This may
include modiﬁed in vivo tests or in vitro tests that may substitute
for in vivo tests. However, this does not necessarily indicate that
the results are any less applicable to the safety assessment of these
proteins.
3.3.1. In vivo animal testing with intractable proteins
3.3.1.1. Acute study. Acute toxicity studies are often conducted in
mice by a single high dose of 2000 mg/kg via oral gavage (OECD,
2001, designed for small molecules). An alternative to this maxi-
mal dose could be a dose based on at least a 100-fold margin of
exposure (Hammond et al., 2013). Routinely, these studies are con-
ducted with puriﬁed proteins. In the case of intractable proteins, a
characterized enriched fraction or substitute protein may be used
with a safety margin as high as possible (if 100-fold cannot be
attained). After dosing, animals are observed daily for 14 days
and changes in body weight and any clinical signs of adverse
effects are recorded. At the end of the in-life phase, animals are
euthanized and a gross necropsy is performed. This kind of study
requires gram-level quantities of protein to dose multiple mice.
Although seldom used, intravenous (IV) administration of the test
substance has been reported as an indication of a lack of toxicity of
the phosphinothricin acetyltransferase (PAT) protein (Hérouet
et al., 2005) and may be an alternative when only a small amount
of protein is available for the acute study. The IV route of exposure
provides high systemic exposure to the active test protein by
avoiding denaturation in low gastric pH, the proteolytic degrada-
tion in the gut, and absorption kinetics, and in one way mimics a
worst-case scenario; however, the protein bypasses the gastroin-
testinal (GI) system and therefore avoids a potential target of the
protein. Also, when protein is produced in a heterologous bacterial
system, a high level of bacterial endotoxin in the protein extract
can lead to false positive results. Therefore, IV testing should be
used with some caution.
3.3.1.2. Repeated-dose study. The purpose of the repeated-dose die-
tary study is to evaluate the test substance’s propensity to elicit
adverse effects in rodents up to 28 days after administration. Com-
monly done for small molecules, laboratory rodents (mice or rats)
are repeatedly exposed to a limit dose of 1000 mg/kg of body
weight of test substance (in accordance with OECD 407 [OECD,
1995]; see Delaney, 2007; Mathesius et al., 2009). Doses have also
been administered at levels of up to 1000 times the estimated
human exposure (Juberg et al., 2009), but such studies require
knowledge of the concentration of the GM protein that is
expressed in the edible part(s) of the GM crop. The endpoints that
are typically measured in repeated-dose studies are more compre-
hensive than those in acute toxicology studies and include clinical
and ophthalmological observations, assessment of body weights,feed consumption, functional observational batteries, motor activ-
ity, clinical chemistry, organ weights, and histopathology (Delaney,
2007).
Repeated-dose toxicology studies with GM proteins at the limit
dose levels require > 20 grams of protein test substance (Delaney
et al., 2008; Juberg et al., 2009; Mathesius et al., 2009), an amount
unlikely to be obtained with intractable proteins. If it is deter-
mined, following Tier I testing, that in vivo toxicology studies are
appropriate, it may be appropriate to test with enriched prepara-
tions containing the recombinant protein of interest. The caveat
is that animal toxicology studies with enriched preparations would
require that analytical methodologies be available to determine
the concentration of the intractable protein in the preparation for
purposes of dose extrapolation to estimated human exposure.
Microsome preparations, as referenced in section 3.2.4 for
digestibility studies, could likewise be useful in in vivo toxicology
studies. The use of microsomes for rodent toxicology studies would
represent an excellent delivery system for integral membrane pro-
teins, but it should be noted that microsomes represent a complex
mixture of lipids and proteins (Han et al., 2001) and the amount of
speciﬁc membrane protein could be extremely low. Nevertheless, if
the concentration of the transmembrane protein in the enriched
fraction is known and can be related to human exposure to deter-
mine margin of exposure, the results should be valid regardless of
the presence of other ingredients in the test substance, particularly
in the case that no adverse effects are observed.
The same considerations hold for using yeast as an expression
and delivery system for in vivo toxicology studies. See Blanquet-
Diot et al. (2007) for the use of yeast in biodrug development
and Powilleit et al. (2007) for use of yeast in vaccine development.
Finally, it should be considered that feeding studies with whole
foods or processed fractions from GM crops may have application
in establishing a margin of exposure through evaluation of the crop
containing intractable protein(s). While the limitations and caveats
described in Bartholomaeus et al. (2013) and Kuiper et al. (2013)
should be considered, this situation could provide information
relating to exposure to the intractable protein(s) in a context that
is more realistic under real-world conditions. In most cases, these
types of studies would be expected to provide a good margin of
exposure relative to humans as the concentrations at which the
food and feed fractions are incorporated are well in excess of
human exposure.
3.3.2. In vitro alternatives to in vivo testing
Most dietary proteins do not cause adverse effects to humans
because they are metabolized into amino acids and small peptides
in the gut that are readily absorbed for nutritive purposes (Delaney
et al., 2008). Conversely, proteins that are known to be toxic to
humans and other animals following oral exposure are often resis-
tant to digestion by the target organism such that they have either
toxicity primarily directed toward intestinal cells (e.g., kidney bean
lectin [Lafont et al., 1988; Rossi et al., 1984; Weinman et al., 1989])
or can also be accompanied by systemic toxicity following absorp-
tion from the GI system (e.g., ricin [Cook et al., 2006; Ishiguro et al.,
1992a, 1992b]). Furthermore, the potential toxicity of proteins
introduced into GM crops has been evaluated in mice or other lab-
oratory animals by exposure to puriﬁed proteins, though to date,
none have demonstrated any evidence of adverse effects (for
example, see Hérouet et al., 2005; Juberg et al., 2009; Mathesius
et al., 2009; Rice et al., 2008).
Using an in vitro model of human intestinal epithelial cells to
investigate the toxicity of proteins as an alternative to in vivo stud-
ies with animals may have merit particularly in the case of intrac-
table proteins when isolation of gram quantities will not be
possible. This model includes many of the structural features found
in the human gastrointestinal system including development of
Table 4
Potential hazard identiﬁcation tasks for intractable proteins.
Task Is puriﬁed
protein
required?
Is conventional
approach possible
with intractable
protein?
Solutions for testing intractable protein Classes of intractable proteins for
which solution is applicable
Limitations of test/approach
History of safe use
(HOSU)
No Yes Systematic review of literature and a summary paper All Data gaps
Conﬂicting results to be interpreted (subjective)
Bioinformatics
analysis
No Yes In silico search with updated databases All False positives may lead to erroneous conclusions
False negatives cannot be detected
Mode of action Yes/No No Use structurally similar proteins with well-established
mode of action to build hypothesis
Most useful for signaling proteins,
transcription factors, R-proteins;
could be used to supplement data in
any category
Lacks direct experimental data
Directed ‘‘omics’’ approaches Need for validation of ‘‘omics’’ data
In vitro digestibility
and heat stability
Yes No Test enriched fractions / grain or crop protein extracts
containing protein of interest
All Difﬁculty in detection and limitations of identifying/
characterizing digest fragments in complex mixture
Expression level and
dietary intake
Protein in
grain/crop
Yes/No Proteomics approach and alternative techniques to
measure protein levels
All Need to deﬁne a robust technique to measure the level of
protein present in plant tissue
Protein equivalence Yes No Isolate protein from a transient or model plant
expression system with alternative promoters/vectors
All, particularly signaling protein and
transcription factors
Plant protein not isolated from the product event
Table 5
Potential hazard characterization tasks for intractable proteins.
Task Is puriﬁed
protein
required?
Is conventional
approach possible
with intractable protein?
Solution for testing intractable protein Classes of intractable proteins for
which solution is applicable
Limitations of test/approach
Acute toxicity study (14-day) Yes No
Limit dose = 2000 mg/kg bw/daya
oral toxicity study
Dose with enriched prep /plant or
recombinant protein extracts Proper
control selection MOEb approach
All for which accurate quantitation
can be made
Limit dose will not be achieved
Testing complex mixture
Repeated-dose toxicity study
(28-day)
Yes No
Limit dose = 1000 mg/kg bw/day
Dose with enriched prep/grain or crop
protein extracts Proper control selection
MOE approach
All for which accurate quantitation
can be made
Limit dose will not be achieved
Testing complex mixture
In vitro testing Yes Yes In vitro cell-based cytotoxicity Proven
robustness and predictability of the test
needed
Most useful for signaling proteins,
transcription factors, and R-proteins
where quantities are limited; could
be used for non-hydrophobic proteins
in any category
Translational argument needs to be made
(cell to whole organism) Not amenable to
hydrophobic proteins
a bw, body weight.
b MOE, margin of exposure.
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disruption in the integrity of intestinal cell monolayers following
exposure to a protein could be considered as a sign of toxicity asso-
ciated with that protein in the presence or absence of direct
cytotoxicity.
The use of cultured intestinal epithelial cells in the safety
assessment process is not entirely new, as they have been used
to predict the bioavailability of drugs with a strong correlation to
in vivo bioavailability studies (Artursson et al., 2012). In addition,
in vitro toxicology using human-derived cells and tissues is emerg-
ing as an alternative to in vivo animal models and has gained
acceptance in some areas of consumer product testing (e.g., cos-
metics). The beneﬁts of using in vitro models for conducting toxi-
cology testing of GM proteins would include a reduction in the
number of animals used in research, substantially less isolated pro-
tein required, high reproducibility, and lower cost.
While there are advantages to in vitro studies, there are limita-
tions as well, including the fact that they cannot model the com-
plexity of the gastrointestinal tract. Though in vitro studies have
been accepted as a model for predicting drug bioavailability, they
have not been validated with universally accepted experimental
endpoints to deﬁne an adverse effect. Additionally, it is not cur-
rently understood how the concentrations of proteins used
in vitro compare with doses of proteins that would be administered
in vivo. In the absence of a validated in vitro model, there can be
many confounding factors that can alter the outcome of the study.
These factors can either affect the cells in culture (i.e., pH, osmolar-
ity, nature and content of media, etc.) or be associated with the test
protein (hydrophilic vs. hydrophobic, purity, etc.), which may con-
found the interpretation of the intrinsic toxicological effects of the
test protein. Finally, this type of modeling may also require special
attention to the positive and negative control substances to be
used experimentally to demonstrate sensitivity and selectivity.
For these reasons, it is not yet known whether an in vitro toxic-
ity test with cultured intestinal epithelial cells can be used as a
replacement for mammalian toxicity studies, but evidence sug-
gests that it should continue to be investigated and remains of con-
siderable interest. Future investigations in this area will likely
focus on determining whether the results obtained from in vitro
studies are similar to those observed in vivo. Determining which
variables to measure and which controls to use will be important
considerations.4. Conclusions
The potential beneﬁts of intractable proteins include a broad
range of valuable traits such as disease resistance, drought toler-
ance, nitrogen use efﬁciency, and enhanced nutrient value. Five
categories of intractable proteins were identiﬁed and described
here: membrane proteins; signaling proteins, transcription factors,
N-glycosylated proteins, and R-proteins. Although each category
has its speciﬁc challenges (Table 1), those common to several are
(1) the very low concentrations of protein produced in planta and
(2) the inability to obtain protein from a heterologous system that
is (or can be adequately demonstrated to be) equivalent to the
plant-produced protein. With the possible exception of N-glycosyl-
ated proteins, many of the same qualities (e.g., low stability and
low quantity) that make these proteins intractable are the same
qualities that indicate lack of hazards in conventional proteins.
Thus the science indicates that thorough safety reviews are not
necessary.
However, the classiﬁcation of a protein as intractable does not
preclude a comprehensive safety assessment of the protein should
one become necessary. The tiered weight-of-evidence approach
published by ILSI in 2008 (Delaney et al., 2008) and themodiﬁcations proposed by Hammond et al. (2013) propose that
the type and extent of testing be tailored based on exposure levels
of the identiﬁed hazards, rather than applied uniformly to every
situation. This approach is particularly important in the case of
intractable proteins, for which some of the conventional hazard
identiﬁcation and characterization tasks are very difﬁcult or
impossible with current technology.
The HOSU and bioinformatics analysis can be completed with-
out isolation of any protein, and can thus be performed regardless
of other challenges (Table 4). HOSU reﬂects knowledge both of the
donor organism and of the protein itself, or of close relatives, which
may have already been consumed by humans with no adverse
effects. Bioinformatics analysis helps to identify which information
on other proteins or species might be applicable to the intractable
protein, as well as whether the protein itself has characteristics
indicative of potential toxicity or allergenicity.
In addition, bioinformatics could provide helpful information
when establishing the mode of action, especially when the nature
of the protein has made it difﬁcult to study directly. The remaining
task in hazard identiﬁcation, assessment of in vitro digestibility,
has typically been performed with pure protein. An alternative to
this approach is to use enriched proteins (e.g., microsome or simi-
lar preparations) from the GM crop or recombinant expression sys-
tem. For integral membrane proteins, this approach has the
advantage that the protein could be tested in its native form. Like-
wise, for those cases in which Tier II testing is judged to be neces-
sary, the acute/repeated-dose tasks could be completed with semi-
pure preparations (Table 5). In cases where enriched samples are
used for feeding, it is necessary to be able to accurately quantitate
the level of protein in the sample.5. Conﬂict of interest statement
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